000157104 001__ 157104
000157104 005__ 20240229123129.0
000157104 0247_ $$2doi$$a10.1093/jrr/rraa042
000157104 0247_ $$2pmid$$apmid:32657322
000157104 0247_ $$2ISSN$$a0449-3060
000157104 0247_ $$2ISSN$$a1349-9157
000157104 037__ $$aDKFZ-2020-01395
000157104 041__ $$aeng
000157104 082__ $$a610
000157104 1001_ $$0P:(DE-He78)132c557ecfe3de184432e5ac8a9c7308$$aSaager, Maria$$b0$$eFirst author
000157104 245__ $$aRamipril reduces incidence and prolongates latency time of radiation-induced rat myelopathy after photon and carbon ion irradiation.
000157104 260__ $$a[Oxford]$$bOxford University Press$$c2020
000157104 3367_ $$2DRIVER$$aarticle
000157104 3367_ $$2DataCite$$aOutput Types/Journal article
000157104 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1675089402_20049
000157104 3367_ $$2BibTeX$$aARTICLE
000157104 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000157104 3367_ $$00$$2EndNote$$aJournal Article
000157104 500__ $$a2020 Sep 8;61(5):791-798#EA:E040#LA:E040#
000157104 520__ $$aTo test the hypothesis that the use of an angiotensin-converting enzyme inhibitor (ACEi) during radiotherapy may be ameliorative for treatment-related normal tissue damage, a pilot study was conducted with the clinically approved (ACE) inhibitor ramipril on the outcome of radiation-induced myelopathy in the rat cervical spinal cord model. Female Sprague Dawley rats were irradiated with single doses of either carbon ions (LET 45 keV/μm) at the center of a 6 cm spread-out Bragg peak (SOBP) or 6 MeV photons. The rats were randomly distributed into 4 experimental arms: (i) photons; (ii) photons + ramipril; (iii) carbon ions and (iv) carbon ions + ramipril. Ramipril administration (2 mg/kg/day) started directly after irradiation and was maintained during the entire follow-up. Complete dose-response curves were generated for the biological endpoint radiation-induced myelopathy (paresis grade II) within an observation time of 300 days. Administration of ramipril reduced the rate of paralysis at high dose levels for photons and for the first time a similar finding for high-LET particles was demonstrated, which indicates that the effect of ramipril is independent from radiation quality. The reduced rate of myelopathy is accompanied by a general prolongation of latency time for photons and for carbon ions. Although the already clinical approved drug ramipril can be considered as a mitigator of radiation-induced normal tissue toxicity in the central nervous system, further examinations of the underlying pathological mechanisms leading to radiation-induced myelopathy are necessary to increase and sustain its mitigative effectiveness.
000157104 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000157104 588__ $$aDataset connected to CrossRef, PubMed,
000157104 7001_ $$aHahn, Eric W$$b1
000157104 7001_ $$0P:(DE-He78)1bf5666dbe17c0fd5e81301c52f6347a$$aPeschke, Peter$$b2
000157104 7001_ $$aBrons, Stephan$$b3
000157104 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, Peter E$$b4$$udkfz
000157104 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b5$$udkfz
000157104 7001_ $$0P:(DE-He78)b43076fb0a30230e4323887c0c980046$$aKarger, Christian$$b6$$eLast author$$udkfz
000157104 773__ $$0PERI:(DE-600)2038914-0$$a10.1093/jrr/rraa042$$gp. rraa042$$n5$$p791-798$$tJournal of radiation research$$v61$$x1349-9157$$y2020
000157104 909CO $$ooai:inrepo02.dkfz.de:157104$$pVDB
000157104 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)132c557ecfe3de184432e5ac8a9c7308$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000157104 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1bf5666dbe17c0fd5e81301c52f6347a$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000157104 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000157104 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000157104 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b43076fb0a30230e4323887c0c980046$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000157104 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000157104 9132_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000157104 9141_ $$y2020
000157104 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Double blind peer review$$d2020-01-12
000157104 915__ $$0LIC:(DE-HGF)CCBYNCNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial CC BY-NC (No Version)$$bDOAJ$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ RADIAT RES : 2018$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-12
000157104 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-12
000157104 9202_ $$0I:(DE-He78)E040-20160331$$kE040$$lE040 Med. Physik in der Strahlentherapie$$x0
000157104 9201_ $$0I:(DE-He78)E040-20160331$$kE040$$lE040 Med. Physik in der Strahlentherapie$$x0
000157104 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x1
000157104 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x2
000157104 9200_ $$0I:(DE-He78)E040-20160331$$kE040$$lE040 Med. Physik in der Strahlentherapie$$x0
000157104 980__ $$ajournal
000157104 980__ $$aVDB
000157104 980__ $$aI:(DE-He78)E040-20160331
000157104 980__ $$aI:(DE-He78)E050-20160331
000157104 980__ $$aI:(DE-He78)E055-20160331
000157104 980__ $$aUNRESTRICTED